179 related articles for article (PubMed ID: 34529322)
41. Repurposing of the approved small molecule drugs in order to inhibit SARS-CoV-2 S protein and human ACE2 interaction through virtual screening approaches.
Kalhor H; Sadeghi S; Abolhasani H; Kalhor R; Rahimi H
J Biomol Struct Dyn; 2022 Feb; 40(3):1299-1315. PubMed ID: 32969333
[TBL] [Abstract][Full Text] [Related]
42. Identification of SARS-CoV-2 Receptor Binding Inhibitors by In Vitro Screening of Drug Libraries.
David AB; Diamant E; Dor E; Barnea A; Natan N; Levin L; Chapman S; Mimran LC; Epstein E; Zichel R; Torgeman A
Molecules; 2021 May; 26(11):. PubMed ID: 34072087
[TBL] [Abstract][Full Text] [Related]
43. In-silico drug repurposing for targeting SARS-CoV-2 main protease (M
Sharma S; Deep S
J Biomol Struct Dyn; 2022 Apr; 40(7):3003-3010. PubMed ID: 33179568
[TBL] [Abstract][Full Text] [Related]
44. Structure-based drug repurposing for targeting Nsp9 replicase and spike proteins of severe acute respiratory syndrome coronavirus 2.
Chandel V; Sharma PP; Raj S; Choudhari R; Rathi B; Kumar D
J Biomol Struct Dyn; 2022 Jan; 40(1):249-262. PubMed ID: 32838660
[TBL] [Abstract][Full Text] [Related]
45. Multi-Targeting Approach in Selection of Potential Molecule for COVID-19 Treatment.
Velagacherla V; Suresh A; Mehta CH; Nayak UY; Nayak Y
Viruses; 2023 Jan; 15(1):. PubMed ID: 36680253
[TBL] [Abstract][Full Text] [Related]
46. A multi-stage virtual screening of FDA-approved drugs reveals potential inhibitors of SARS-CoV-2 main protease.
Mandour YM; Zlotos DP; Alaraby Salem M
J Biomol Struct Dyn; 2022 Mar; 40(5):2327-2338. PubMed ID: 33094680
[TBL] [Abstract][Full Text] [Related]
47. Selection of SARS-CoV-2 main protease inhibitor using structure-based virtual screening.
Hakami AR; Bakheit AH; Almehizia AA; Ghazwani MY
Future Med Chem; 2022 Jan; 14(2):61-79. PubMed ID: 34814706
[No Abstract] [Full Text] [Related]
48. Repurposing of renin inhibitors as SARS-COV-2 main protease inhibitors: A computational study.
Refaey RH; El-Ashrey MK; Nissan YM
Virology; 2021 Feb; 554():48-54. PubMed ID: 33370597
[TBL] [Abstract][Full Text] [Related]
49. Lead Finding from Selected Flavonoids with Antiviral (SARS-CoV-2) Potentials Against COVID-19: An In-silico Evaluation.
Gorla US; Rao K; Kulandaivelu US; Alavala RR; Panda SP
Comb Chem High Throughput Screen; 2021; 24(6):879-890. PubMed ID: 32819226
[TBL] [Abstract][Full Text] [Related]
50. In Silico Drug Repositioning to Target the SARS-CoV-2 Main Protease as Covalent Inhibitors Employing a Combined Structure-Based Virtual Screening Strategy of Pharmacophore Models and Covalent Docking.
Vázquez-Mendoza LH; Mendoza-Figueroa HL; García-Vázquez JB; Correa-Basurto J; García-Machorro J
Int J Mol Sci; 2022 Apr; 23(7):. PubMed ID: 35409348
[TBL] [Abstract][Full Text] [Related]
51. Virtual screening and repurposing of FDA approved drugs against COVID-19 main protease.
Kandeel M; Al-Nazawi M
Life Sci; 2020 Jun; 251():117627. PubMed ID: 32251634
[TBL] [Abstract][Full Text] [Related]
52. In silico study of azithromycin, chloroquine and hydroxychloroquine and their potential mechanisms of action against SARS-CoV-2 infection.
Braz HLB; Silveira JAM; Marinho AD; de Moraes MEA; Moraes Filho MO; Monteiro HSA; Jorge RJB
Int J Antimicrob Agents; 2020 Sep; 56(3):106119. PubMed ID: 32738306
[TBL] [Abstract][Full Text] [Related]
53. Haste makes waste: A critical review of docking-based virtual screening in drug repurposing for SARS-CoV-2 main protease (M-pro) inhibition.
Macip G; Garcia-Segura P; Mestres-Truyol J; Saldivar-Espinoza B; Ojeda-Montes MJ; Gimeno A; Cereto-Massagué A; Garcia-Vallvé S; Pujadas G
Med Res Rev; 2022 Mar; 42(2):744-769. PubMed ID: 34697818
[TBL] [Abstract][Full Text] [Related]
54. Structure-based identification of SARS-CoV-2 main protease inhibitors from anti-viral specific chemical libraries: an exhaustive computational screening approach.
Bhowmick S; Saha A; Osman SM; Alasmary FA; Almutairi TM; Islam MA
Mol Divers; 2021 Aug; 25(3):1979-1997. PubMed ID: 33844135
[TBL] [Abstract][Full Text] [Related]
55. Molecular Docking and Virtual Screening Based Prediction of Drugs for COVID-19.
Talluri S
Comb Chem High Throughput Screen; 2021; 24(5):716-728. PubMed ID: 32798373
[TBL] [Abstract][Full Text] [Related]
56. In silico study of the potential interactions of 4'-acetamidechalcones with protein targets in SARS-CoV-2.
Q Almeida-Neto FW; Castro Matos MG; Marinho EM; Marinho MM; Róseo Paula Pessoa Bezerra de Menezes R; Sampaio TL; Bandeira PN; Celedonio Fernandes CF; Magno Rodrigues Teixeira A; Marinho ES; de Lima-Neto P; Silva Dos Santos H
Biochem Biophys Res Commun; 2021 Jan; 537():71-77. PubMed ID: 33387885
[TBL] [Abstract][Full Text] [Related]
57. Virtual screening and molecular dynamics simulations provide insight into repurposing drugs against SARS-CoV-2 variants Spike protein/ACE2 interface.
Pirolli D; Righino B; Camponeschi C; Ria F; Di Sante G; De Rosa MC
Sci Rep; 2023 Jan; 13(1):1494. PubMed ID: 36707679
[TBL] [Abstract][Full Text] [Related]
58. Anti-HCV and anti-malaria agent, potential candidates to repurpose for coronavirus infection: Virtual screening, molecular docking, and molecular dynamics simulation study.
Hosseini FS; Amanlou M
Life Sci; 2020 Oct; 258():118205. PubMed ID: 32777300
[TBL] [Abstract][Full Text] [Related]
59. Structure-based virtual screening, molecular dynamics and binding affinity calculations of some potential phytocompounds against SARS-CoV-2.
Naik SR; Bharadwaj P; Dingelstad N; Kalyaanamoorthy S; Mandal SC; Ganesan A; Chattopadhyay D; Palit P
J Biomol Struct Dyn; 2022 Sep; 40(15):6921-6938. PubMed ID: 33682632
[TBL] [Abstract][Full Text] [Related]
60. Structure-based virtual screening suggests inhibitors of 3-Chymotrypsin-Like Protease of SARS-CoV-2 from Vernonia amygdalina and Occinum gratissimum.
Gyebi GA; Elfiky AA; Ogunyemi OM; Ibrahim IM; Adegunloye AP; Adebayo JO; Olaiya CO; Ocheje JO; Fabusiwa MM
Comput Biol Med; 2021 Sep; 136():104671. PubMed ID: 34332348
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
